Kura Oncology, Inc. (KURA): Results of Operations and Financial Condition
Kura Oncology, Inc. (KURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kura Oncology Reports SECOND Quarter 2026 Financial Results – KOMZIFTI ® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q – – KOMZIFTI ® achieved majority share of new patient starts
How this was made
The 30-second read
Why it matters
Traders can update near-term expectations for KOMZIFTI adoption based on revenue growth, new patient starts, and prescription trends, while also monitoring upcoming 2H 2026 clinical readouts that could affect valuation multiples.
Market read
Fresh, quantified launch momentum and cash/collaboration expectations can drive short-term biotech sentiment and estimate revisions ahead of 2H 2026 clinical catalysts.
What to watch
The filing emphasizes TAM and leadership claims, but it does not provide guidance, margin detail, or explicit collaboration payment timing beyond an anticipated $180M.
Kura Oncology Reports SECOND Quarter 2026 Financial Results – KOMZIFTI ® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q
KOMZIFTI commercialization showed sequential momentum, with $9.1 million in net product revenue, approximately 115 new patient starts, and more than 250 total prescriptions, while Kura reported a $68.3 million net loss and cash, cash equivalents and short-term investments of $519.0 million.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| KOMZIFTI net product revenueother | $9.1 million | 57% increase from 1Q 2026 | – |
| Collaboration revenueother | $11.8 million | – | – |
| Research and development expensesother | $61.9 million | – | – |
| Selling, general and administrative expensesother | $31.8 million | – | – |
| Net lossother | $68.3 million | – | – |
| Non-cash, share-based compensation expenseother | $8.2 million | – | – |
| Cash, cash equivalents and short-term investmentsother | $519.0 million | – | – |
| KOMZIFTI new patient startsother | Approximately 115 new patient starts (NPS) | 35% increase from 1Q 2026 | – |
| KOMZIFTI total prescriptionsother | More than 250 total prescriptions (TRx) in 2Q 2026 | 59% increase from 1Q 2026 | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| KOMZIFTI commercial launchApproximately 115 new patient starts, more than 250 total prescriptions including repeat prescriptions, broader adoption across academic and community treatment centers, and physician-directed use in combination with established standards of care. | $9.1 million in net product revenue | 57% increase from 1Q 2026 | – |
2026 through 2H 2027 outlook
- NoteKura expects multiple commercial and clinical catalysts over the next 12 to 18 months.
- NoteDeliver sustained quarter-over-quarter growth.
- NoteUpdated long-term KOMET-007 Phase 1b data in newly diagnosed, intensive chemotherapy-ineligible NPM1-m AML patients: 2H 2026.
- NoteInitial KOMET-007 Phase 1b data with 7+3 intensive chemotherapy and quizartinib in newly diagnosed NPM1-m/FLT3-ITD AML: 2H 2026.
- NoteInitial KOMET-008 data with gilteritinib in R/R NPM1-m/FLT3-m AML: 2H 2026.
- NoteExploratory KOMET-001 monotherapy analysis in MEIS1-associated AML subtypes: 2H 2026.
- NoteComplete enrollment in the randomized FIT-001 Phase 1b study in cabozantinib-naïve ccRCC: 1H 2027.
- NoteReport initial clinical data from the randomized FIT-001 Phase 1b study: 2H 2027.
- NoteInitiate a platform study of darlifarnib plus daraxonrasib in KRAS-mutant 2L+ PDAC: 1H 2027.
- NoteCurrent cash resources will be sufficient to fund the ziftomenib AML program through topline results from the first pivotal Phase 3 KOMET-017 trial, anticipated in 2028.
What drove it
- KOMZIFTI achieved a majority share of new patient starts in the R/R NPM1-m AML menin inhibitor class in its second full quarter on the market.
- EHA 2026 long-term KOMET-007 data for 600 mg ziftomenib plus intensive chemotherapy in 99 patients with newly diagnosed NPM1-m or KMT2A-r AML showed CRc rates of 96% and 90%, respectively, and 12-month OS rates of 94% and 71%, respectively.
- Updated KOMET-007 results in R/R NPM1-m AML reported an 87% ORR and 70% CRc rate in venetoclax-naïve patients. Median duration of CRc was 9.2 months, and median OS was not reached after 10.7 months of follow-up.
- Darlifarnib plus adagrasib data showed tumor shrinkage in 77% of response-evaluable patients and confirmed ORRs of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer.
- Darlifarnib plus cabozantinib in cabozantinib-naïve clear cell renal cell carcinoma showed ORRs of up to 50% across dose levels and an mPFS of 13 months.
- In cabozantinib-exposed clear cell renal cell carcinoma, darlifarnib plus cabozantinib achieved a 44% ORR, 94% disease control rate, and tumor shrinkage in 75% of patients.
Concerns
- Collaboration revenue was $11.8 million, compared to $15.3 million for 2Q 2025.
- SG&A expenses were $31.8 million, compared to $25.2 million for 2Q 2025.
- Net loss was $68.3 million, compared to $66.1 million for 2Q 2025.
- Cash, cash equivalents and short-term investments were $519.0 million as of June 30, 2026, compared to $667.2 million as of December 31, 2025.
- Clinical and commercial milestones remain prospective, including data presentations anticipated in 2H 2026 and darlifarnib study milestones in 1H 2027 and 2H 2027.
What to watch
- Sustained quarter-over-quarter growth in KOMZIFTI net product revenue, new patient starts, total prescriptions, repeat prescribing, and physician adoption.
- Updated and initial ziftomenib clinical data anticipated in 2H 2026 from KOMET-007, KOMET-008, and KOMET-001.
- Progress of enrollment across KOMET-017 frontline registrational studies, KOMET-008, and the KOMET-007 cohort evaluating ziftomenib plus quizartinib and intensive chemotherapy.
- Completion of FIT-001 Phase 1b enrollment in 1H 2027 and initial clinical data in 2H 2027.
- The anticipated $180 million in collaboration payments from Kyowa Kirin and the stated cash runway through anticipated 2028 Phase 3 KOMET-017 topline results.
Balance sheet and cash flow
- $519.0 million in cash, cash equivalents and short-term investments as of June 30, 2026, compared to $667.2 million as of December 31, 2025.
- $180 million in anticipated collaboration payments from Kyowa Kirin.
- The Company believes its current cash resources will be sufficient to fund the ziftomenib AML program through topline results from the first pivotal Phase 3 KOMET-017 trial, anticipated in 2028.
Analysis
Kura reported early commercial momentum for KOMZIFTI in its second full quarter of launch. Net product revenue was $9.1 million, a 57% increase from 1Q 2026. Approximately 115 new patient starts rose 35% from 1Q 2026, while more than 250 total prescriptions, including repeat prescriptions, rose 59% from 1Q 2026. The company also said KOMZIFTI achieved a majority share of new patient starts in the R/R NPM1-m AML menin inhibitor class.
The revenue mix included $11.8 million of collaboration revenue, compared to $15.3 million for 2Q 2025. Kura did not report total revenue in the provided release. Research and development expenses were $61.9 million, compared to $62.8 million for 2Q 2025, while SG&A expenses increased to $31.8 million from $25.2 million. Net loss was $68.3 million, compared to $66.1 million for 2Q 2025, and included $8.2 million in non-cash, share-based compensation expense.
Clinical execution remains centered on expanding ziftomenib across AML settings and developing darlifarnib combinations in solid tumors. Long-term KOMET-007 data and updated data in R/R NPM1-m AML were cited as support for ongoing frontline and combination programs. The company also highlighted darlifarnib activity across KRAS G12C-mutated tumors and clear cell renal cell carcinoma, with the randomized FIT-001 Phase 1b study continuing enrollment.
Liquidity was $519.0 million in cash, cash equivalents and short-term investments as of June 30, 2026, compared to $667.2 million as of December 31, 2025. Kura additionally cited $180 million in anticipated collaboration payments from Kyowa Kirin and stated that current cash resources should fund the ziftomenib AML program through topline results from the first pivotal Phase 3 KOMET-017 trial, anticipated in 2028. The release provided no financial revenue, margin, expense, or tax-rate guidance, leaving commercial trajectory and upcoming 2H 2026 clinical updates as the principal disclosed near-term markers.
Management, verbatim
In only its second full quarter of launch, KOMZIFTI established early leadership in relapsed or refractory NPM1 -mutant AML, achieving a majority share of new patient starts in the menin inhibitor class.
Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology
Not in the filing
stated, not guessed- Total revenue.
- Gross profit and gross margin.
- Operating income or operating loss.
- GAAP and non-GAAP diluted EPS.
- Non-GAAP revenue, expenses, operating income or loss, net income or loss, and EPS.
- Prior-quarter collaboration revenue, R&D expenses, SG&A expenses, net loss, and share-based compensation expense.
- Year-over-year percentage changes for collaboration revenue, R&D expenses, SG&A expenses, net loss, share-based compensation expense, and cash.
- Operating cash flow and free cash flow.
- Debt.
- Share repurchases, dividends, and other capital returns.
- Financial guidance for revenue, gross margin, operating expenses, and tax rate.
- Prior-quarter outlook for comparison.
- Reportable operating segments and segment revenue beyond KOMZIFTI net product revenue.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This SEC 8-K (Item 2.02) reports Kura’s 2Q 2026 financial results and program/catalyst updates for KOMZIFTI (ziftomenib) and darlifarnib.
Ticker impact
Kura reported 2Q 2026 KOMZIFTI net product revenue of $9.1M, up 57% vs 1Q, plus ~115 new patient starts, up 35%.
Likely positive bias for near-term trading as investors digest accelerating launch metrics and improved commercial momentum.
This is a primary SEC filing with specific, time-stamped operating metrics (revenue, prescriptions, patient starts) and balance-sheet/collaboration cash expectations, which can move biotech sentiment and estimates.
Market effects
Reinforces investor appetite for early commercial-stage oncology launches, especially menin inhibitor class adoption signals in NPM1-mutant AML.
Primarily US biotech sentiment, with potential spillover to small-cap oncology peers tracking launch execution.
EHA/ASCO-linked clinical updates may influence global AML and solid-tumor precision medicine expectations.
Counterpoint
Commercial metrics are early-quarter launch indicators; investors may discount them if longer-term retention, pricing, and payer coverage are not yet proven.
Key entities
- issuerKura Oncology, Inc.
Nasdaq-listed biopharmaceutical company reporting 2Q 2026 KOMZIFTI commercial and financial results plus pipeline updates.
- productKOMZIFTI (ziftomenib)
Menin inhibitor highlighted for early leadership in R/R NPM1-mutant AML with reported commercial traction metrics.
- product_candidatedarlifarnib
Precision combination platform in solid tumors with Phase 1 FIT-001 updates cited for KRAS G12C and renal cell carcinoma settings.
